Vaccines (May 2023)

Chemokine Levels among Patients with Middle East Respiratory Syndrome Coronavirus Infection

  • Abdulkarim Alhetheel,
  • Ahmed Albarrag,
  • Zahid Shakoor,
  • Ali Somily,
  • Mazin Barry,
  • Haifa Altalhi,
  • Muhammed Bakhrebah,
  • Majed Nassar,
  • Mohamed Alfageeh,
  • Ayed Assiri,
  • Sarah Alfaraj,
  • Ziad Memish

DOI
https://doi.org/10.3390/vaccines11061048
Journal volume & issue
Vol. 11, no. 6
p. 1048

Abstract

Read online

Middle East respiratory syndrome coronavirus (MERS-CoV) is associated with significant morbidity and mortality due to intense pulmonary inflammation. Enhanced chemokine-mediated leukocyte infiltration in lungs has been linked with unfavorable outcomes with respect to the disease. This cross-sectional study assessed the levels of chemokines among 46 MERS-CoV-infected patients (19 asymptomatic and 27 symptomatic) and 52 healthy controls using a customized Luminex human chemokine magnetic multiplex panel. The plasma levels of interferon-inducible protein (IP)-10 (568.5 ± 114.7 vs. 55.19 ± 5.85 pg/mL; p p p p p p p p p p p p < 0.004) was significantly higher in deceased symptomatic patients compared to recovered symptomatic patients. MCP-1 was the only chemokine associated with a higher risk of mortality. Symptomatic MERS-CoV-infected patients had a significant elevation of plasma chemokines and elevated MCP-1 levels were found to be associated with fatal outcomes.

Keywords